In vitro and in vivo anti-melanoma effects of ciglitazone

Journal of Investigative Dermatology

Volumn 129, Issue 5, 2009, Pages 1208-1218

  Botton, Thomas ^a,b   Puissant, Alexandre ^a,b   Bahadoran, Philippe ^a,b,c   Annicotte, Jean Sebastien ^d   Fajas, Lluis ^d   Ortonne, J P ^a,b,c   Gozzerino, Genevieve ^a,b   Zamoum, Thamilla ^a,b   Tartare Deckert, Sophie ^a,b   Bertolotto, Corine ^a,b   Ballotti, Robert ^a,b   Rocchi, Stephane ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CIGLITAZONE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; DIMETHYL SULFOXIDE; M 1944; PEGLICOL 5 OLEATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOPROTEIN; PIOGLITAZONE; PRB PROTEIN; PROTEIN P21; ROSIGLITAZONE; STAUROSPORINE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL LOSS; CELL MEMBRANE POTENTIAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; MITOCHONDRIAL MEMBRANE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 65049088109     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.346     Document Type: Article

References (48)

1. Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A et al. (2006) Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147:4463-75
2. Akasaki Y, Liu G, Matundan HH, Ng H, Yuan X, Zeng Z et al. (2006) A peroxisome proliferator-activated receptor-gamma agonist troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1 B on human glioma cells. J Biol Chem 281:6165-74
3. Avis I, Hong SH, Martinez A, Moody T, Choi YH, Trepel J et al. (2001) Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J 15:2007-9
4. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP (2003) Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase Il study. Breast Cancer Res Treat 79:391-7
5. Chang TH, Szabo E (2000) Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in nonsmall cell lung cancer. Cancer Res 60:1129-38
6. Chung SH, Onoda N, Ishikawa T, Ogisawa K, Takenaka C, Yano Y et al. (2002) Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn J Cancer Res 93:1358-65
7. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF (2001) Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 3:339-45
8. Demierre MF (2006) Epidemiology and prevention of cutaneous melanoma. Curr Treat Options Oncol 7:181-6
9. Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-88
10. Freudlsperger C, Moll I, Schumacher U, Thies A (2006) Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells In vitro. Anticancer Drugs 17:325-32
11. Goodall J, Martinozzi S, Dexter TJ, Champeval D, Carreira S, Larue L et al. (2004) Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol Cell Biol 24:2915-22
12. Grommes C, Landreth GE, Heneka MT (2004) Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5:419-29
13. Hilmi C, Larribere L, Deckert M, Rocchi S, Giuliano S, Bille K et al. (2008a) Involvement of FKHRL1 in melanoma cell survival and death. Pigment Cell Melanoma Res 21:139-46
14. Hilmi C, Lamberé L, Ciuliano S, Bille K, Ortonne JP, Ballotti R et al. (2008b) IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin. J Invest Dermatol 128:1499-505
15. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP (2000) Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 60:5494-8
16. Katsuda K, Kataoka M, Uno F, Murakami T, Kondo T, Roth JA et al. (2002) Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene 21:2108-13
17. Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K, Kiyosawa K (2002) Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 24:1-7
18. Koutnikova H, Auwerx J (2002) PPARgamma, an X-ceptor for Xs. Ann NY Acad Sei 967:28-33
19. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S et al. (1998) Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58:3344-52
20. Larribere L, Khaled M, Tartare-Deckert S, Busca R, Luciano F, Bille K et al. (2004) PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 11:1084-91
21. Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123:993-9
22. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M (2003) Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene 22:3162-71
23. Liu Y, Meng Y, Liu H, Li J, Fu J, Chen X (2006) Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line a375. Med Oncol 23:393-402
24. Martelli ML, luliano R, Le Pera I, Sama I, Monaco C, Cammarota S et al. (2002) Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 87:4728-35
25. Michalik L, Desvergne B, Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4:61-70
26. Miot-Noirault E, Legault J, Cachin F, Mounetou E, Degoul F, Gaudreault RC et al. (2004) Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma. Invest New Drugs 22:369-78
27. Mossner R, Schulz U, Kruger U, Middel P, Schinner S, Fuzesi L et al. (2002) Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 119:576-82
28. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS et al. (2000) Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97:10990-5
29. Nunez NP, Liu H, Meadows GG (2006) PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett 236:133-41
30. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T (2001) Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 86:2170-7
31. Placha W, Gil D, Dembinska-Kiec A, Laidler P (2003) The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 13:447-56
32. Qin C, Burghardt R, Smith R, Wormke M, Stewart. J, Safe S (2003) Peroxisome proliferator-activated receptor gamma agonists induce proteasomedependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 63:958-64
33. Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E et al. (2006) SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 66:7516-23
34. Rocchi S, Auwerx J (1999) Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator. Ann Med 31:342-51
35. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D et al. (2001) A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8:737-47
36. Rohn TT, Wong SM, Cotman CW, Cribbs DH (2001) 15-deoxy-delta12,14- prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor-gamma, induces neuronal apoptosis. Neuroreport 12:839-43
37. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, PartridgeJB et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046-52
38. Schoonjans K, Auwerx J (2000) Thiazolidinediones: an update. Lancet 355:1008-10
39. Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclindependent kinases. Genes Dev 18:2699-711
40. Shiau CW, Yang CC, KuIp SK, Chen KF, Chen CS, Huang JW et al. (2005) Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 65:1561-9
41. Strakova N, Ehrmann J, Dzubak P, Bouchal J, Kolar Z (2004) The synthetic ligand of peroxisome proliferator-activated receptor-gamma ciglitazone affects human glioblastoma cell lines. J Pharmacol Exp Ther 309:1239-47
42. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Brun RP et al. (1997) Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 94:237-41
43. Toyoda M, Takagi H, Horiguchi N, Kakizaki S, Sato K, Takayama H et al. (2002) A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50:563-7
44. Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M et al. (2001) Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol 21:3057-70
45. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS (2006) Beyond peroxisome proliferator-activated receptor gamma signaling: the multifacets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 13:401-13
46. Woo M, Hakem R, Furlonger C, Hakem A, Duncan GS, Sasaki T et al. (2003) Caspase-3 regulates cell cycle in B cells: a consequence of substrate specificity. Nat Immunol 4:1016-22
47. Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu JP, Guo YL et al. (2005) Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 26:753-61
48. Zander T, Kraus JA, Grommes C, Schlegel U, Feinstem D, Klockgether T et al. (2002) Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem 81:1052-60